Editas Medical在Evercore上升级CRISPR平台

2024-11-07 02:59

Evercore ISI upgraded Editas Medicine (NASDAQ:EDIT) to outperform from in line citing its status as the exclusive licensor of a type of CRISPR technology used in the development of gene editing therapies.
The firm raised its target price to $7 from $3 (~124% upside based on Nov. 5 close).
Analyst Liisa Bayko noted that Editas is the exclusive licensor of Cas 9 and 12a CRISPR technology through, respectively, 2033 and 2035, adding that it would seek to sublicense the tech to at least 35 programs utilizing Cas 9 or 12a.
She estimated that the technology alone is worth $1.30 a share,
Bayko also attributes $2 in share value to reni-cel, its gene-editing treatment for severe sickle cell disease and transfusion-dependent beta thalassemia.
"We believe that unlocking in vivo editing for SCD could be a game changer as it will significantly expand the addressable patient population by avoiding toxic conditioning regimen," she wrote.

More on Editas Medicine